Literature DB >> 15820462

Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis.

N Jallali1, S Withey, P E Butler.   

Abstract

BACKGROUND: Necrotizing fasciitis (NF) is an uncommon but serious infection of fascia and skin associated with considerable morbidity and mortality. One modality proposed for improving the outcome of this condition is hyperbaric oxygen (HBO) therapy. This is a form of medical treatment that involves intermittent inhalation of 100% oxygen under pressures exceeding the atmosphere. The aim of this article is to review current practice and evidence for the use of HBO as adjunctive therapy in the management of NF.
METHODS: A survey of published English literature through searches of Medline and PubMed was carried out using the following key words: "necrotizing fasciitis," "Fournier's gangrene," "necrotizing soft tissue infections," "hyperbaric oxygen therapy," "and hyperbaric oxygen chambers."
RESULTS: The results of studies on the use of HBO therapy in NF are inconsistent. Some studies have demonstrated that HBO can improve patient survival and decrease the number of debridements required to achieve wound control, whereas others have failed to show any beneficial effect.
CONCLUSIONS: Encouraging results have been achieved with the addition of HBO therapy to standard treatment regimes, thus justifying further research in this field. More robust evidence by way of a prospective randomized trial is necessary before widespread and routine use of HBO in the management of NF can be recommended.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820462     DOI: 10.1016/j.amjsurg.2005.01.012

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  31 in total

Review 1.  Evaluation and Management of Necrotizing Soft Tissue Infections.

Authors:  Stephanie L Bonne; Sameer S Kadri
Journal:  Infect Dis Clin North Am       Date:  2017-09       Impact factor: 5.982

2.  Hyperbaric oxygen therapy in necrotising soft tissue infections: a study of patients in the United States Nationwide Inpatient Sample.

Authors:  Chai R Soh; Ricardo Pietrobon; John J Freiberger; Sophia T Chew; Dimple Rajgor; Mihir Gandhi; Jatin Shah; Richard E Moon
Journal:  Intensive Care Med       Date:  2012-04-20       Impact factor: 17.440

3.  [Affections of the external genitalia and their management].

Authors:  R Rossi; H Rübben
Journal:  Urologe A       Date:  2010-12       Impact factor: 0.639

4.  Diagnosis and management of necrotizing fasciitis of the head and neck.

Authors:  Haldun Oguz; M Sinan Yilmaz
Journal:  Curr Infect Dis Rep       Date:  2012-04       Impact factor: 3.725

5.  Recent advances in the treatment of necrotizing fasciitis.

Authors:  Marina S Morgan
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

6.  Experience in management of Fournier's gangrene: a report of 24 cases.

Authors:  Longwang Wang; Xiaomin Han; Mei Liu; Yan Ma; Bing Li; Feng Pan; Wencheng Li; Liang Wang; Xiong Yang; Zhaohui Chen; Fuqing Zeng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-10-18

7.  Not just full of hot air: hyperbaric oxygen therapy increases survival in cases of necrotizing soft tissue infections.

Authors:  Joshua J Shaw; Charles Psoinos; Timothy A Emhoff; Shimul A Shah; Heena P Santry
Journal:  Surg Infect (Larchmt)       Date:  2014-05-01       Impact factor: 2.150

8.  Clinical classification of cervical necrotizing fasciitis.

Authors:  Emmanuel Kofi Amponsah; Paul Frimpong; Mi Young Eo; Soung Min Kim; Suk Keun Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-09-29       Impact factor: 2.503

Review 9.  Hyperbaric oxygen therapy.

Authors:  Jayesh Shah
Journal:  J Am Col Certif Wound Spec       Date:  2010-04-24

10.  Contemporary trends in necrotizing soft-tissue infections in the United States.

Authors:  Charles M Psoinos; Julie M Flahive; Joshua J Shaw; Youfu Li; Sing Chau Ng; Jennifer F Tseng; Heena P Santry
Journal:  Surgery       Date:  2013-02-27       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.